[1]
Ceccato F, Torchio M, Tizianel I, Peleg Falb M, Barbot M, Sabbadin C, Betterle C, Scaroni C. Renin and electrolytes indicate the mineralocorticoid activity of fludrocortisone: a 6 year study in primary adrenal insufficiency. Journal of endocrinological investigation. 2023 Jan:46(1):111-122. doi: 10.1007/s40618-022-01889-1. Epub 2022 Aug 10
[PubMed PMID: 35947299]
[2]
Rowlands A, Deeb A, Ladjouze A, Hamza RT, Musa SA, Raza J, Jennane F, Abu-Libdeh A, Chanoine JP, GPED CAH Working Group. Access to fludrocortisone and to hydrocortisone in children with congenital adrenal hyperplasia in the WHO Eastern Mediterranean Region: it takes a village…. BMJ global health. 2021 Oct:6(10):. doi: 10.1136/bmjgh-2021-007195. Epub
[PubMed PMID: 34675026]
[3]
Speiser PW, Arlt W, Auchus RJ, Baskin LS, Conway GS, Merke DP, Meyer-Bahlburg HFL, Miller WL, Murad MH, Oberfield SE, White PC. Congenital Adrenal Hyperplasia Due to Steroid 21-Hydroxylase Deficiency: An Endocrine Society Clinical Practice Guideline. The Journal of clinical endocrinology and metabolism. 2018 Nov 1:103(11):4043-4088. doi: 10.1210/jc.2018-01865. Epub
[PubMed PMID: 30272171]
Level 1 (high-level) evidence
[4]
Shen WK, Sheldon RS, Benditt DG, Cohen MI, Forman DE, Goldberger ZD, Grubb BP, Hamdan MH, Krahn AD, Link MS, Olshansky B, Raj SR, Sandhu RK, Sorajja D, Sun BC, Yancy CW. 2017 ACC/AHA/HRS Guideline for the Evaluation and Management of Patients With Syncope: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Circulation. 2017 Aug 1:136(5):e60-e122. doi: 10.1161/CIR.0000000000000499. Epub 2017 Mar 9
[PubMed PMID: 28280231]
Level 1 (high-level) evidence
[5]
Peixoto AJ. Evaluation and management of orthostatic hypotension: Limited data, limitless opportunity. Cleveland Clinic journal of medicine. 2022 Jan 4:89(1):36-45. doi: 10.3949/ccjm.89gr.22001. Epub 2022 Jan 4
[PubMed PMID: 34983800]
[6]
Sheldon RS, Grubb BP 2nd, Olshansky B, Shen WK, Calkins H, Brignole M, Raj SR, Krahn AD, Morillo CA, Stewart JM, Sutton R, Sandroni P, Friday KJ, Hachul DT, Cohen MI, Lau DH, Mayuga KA, Moak JP, Sandhu RK, Kanjwal K. 2015 heart rhythm society expert consensus statement on the diagnosis and treatment of postural tachycardia syndrome, inappropriate sinus tachycardia, and vasovagal syncope. Heart rhythm. 2015 Jun:12(6):e41-63. doi: 10.1016/j.hrthm.2015.03.029. Epub 2015 May 14
[PubMed PMID: 25980576]
Level 3 (low-level) evidence
[7]
Benner BJM, Alsma J, Feelders RA. Hyponatraemia and hyperpigmentation in primary adrenal insufficiency. BMJ case reports. 2019 Mar 7:12(3):. doi: 10.1136/bcr-2018-227200. Epub 2019 Mar 7
[PubMed PMID: 30850564]
Level 3 (low-level) evidence
[8]
Annane D, Renault A, Brun-Buisson C, Megarbane B, Quenot JP, Siami S, Cariou A, Forceville X, Schwebel C, Martin C, Timsit JF, Misset B, Ali Benali M, Colin G, Souweine B, Asehnoune K, Mercier E, Chimot L, Charpentier C, François B, Boulain T, Petitpas F, Constantin JM, Dhonneur G, Baudin F, Combes A, Bohé J, Loriferne JF, Amathieu R, Cook F, Slama M, Leroy O, Capellier G, Dargent A, Hissem T, Maxime V, Bellissant E, CRICS-TRIGGERSEP Network. Hydrocortisone plus Fludrocortisone for Adults with Septic Shock. The New England journal of medicine. 2018 Mar 1:378(9):809-818. doi: 10.1056/NEJMoa1705716. Epub
[PubMed PMID: 29490185]
[9]
Gomes LG, Madureira G, Mendonca BB, Bachega TA. Mineralocorticoid replacement during infancy for salt wasting congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Clinics (Sao Paulo, Brazil). 2013:68(2):147-52
[PubMed PMID: 23525308]
[10]
Hughes IA, Wilton A, Lole CA, Gray OP. Continuing need for mineralocorticoid therapy in salt-losing congenital adrenal hyperplasia. Archives of disease in childhood. 1979 May:54(5):350-5
[PubMed PMID: 475410]
[11]
Teja B, Berube M, Pereira TV, Law AC, Schanock C, Pang B, Wunsch H, Walkey AJ, Bosch NA. Effectiveness of Fludrocortisone Plus Hydrocortisone Versus Hydrocortisone Alone in Septic Shock: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials. American journal of respiratory and critical care medicine. 2024 Jan 25:():. doi: 10.1164/rccm.202310-1785OC. Epub 2024 Jan 25
[PubMed PMID: 38271488]
Level 1 (high-level) evidence
[12]
Polito A, Hamitouche N, Ribot M, Polito A, Laviolle B, Bellissant E, Annane D, Alvarez JC. Pharmacokinetics of oral fludrocortisone in septic shock. British journal of clinical pharmacology. 2016 Dec:82(6):1509-1516. doi: 10.1111/bcp.13065. Epub 2016 Aug 22
[PubMed PMID: 27416887]
[13]
Bamberg K, William-Olsson L, Johansson U, Jansson-Löfmark R, Hartleib-Geschwindner J. The selective mineralocorticoid receptor modulator AZD9977 reveals differences in mineralocorticoid effects of aldosterone and fludrocortisone. Journal of the renin-angiotensin-aldosterone system : JRAAS. 2019 Jan-Mar:20(1):1470320319827449. doi: 10.1177/1470320319827449. Epub
[PubMed PMID: 30813831]
[14]
Joglar JA, Kapa S, Saarel EV, Dubin AM, Gorenek B, Hameed AB, Lara de Melo S, Leal MA, Mondésert B, Pacheco LD, Robinson MR, Sarkozy A, Silversides CK, Spears D, Srinivas SK, Strasburger JF, Tedrow UB, Wright JM, Zelop CM, Zentner D. 2023 HRS expert consensus statement on the management of arrhythmias during pregnancy. Heart rhythm. 2023 Oct:20(10):e175-e264. doi: 10.1016/j.hrthm.2023.05.017. Epub 2023 May 19
[PubMed PMID: 37211147]
Level 3 (low-level) evidence
[15]
Taplin CE, Cowell CT, Silink M, Ambler GR. Fludrocortisone therapy in cerebral salt wasting. Pediatrics. 2006 Dec:118(6):e1904-8
[PubMed PMID: 17101713]
[16]
Yi S, Kong YH, Kim SJ. Fludrocortisone in Pediatric Vasovagal Syncope: A Retrospective, Single-Center Observational Study. Journal of clinical neurology (Seoul, Korea). 2021 Jan:17(1):46-51. doi: 10.3988/jcn.2021.17.1.46. Epub
[PubMed PMID: 33480198]
Level 2 (mid-level) evidence
[17]
Bhattacharyya A, Tymms DJ. Heart failure with fludrocortisone in Addison's disease. Journal of the Royal Society of Medicine. 1998 Aug:91(8):433-4
[PubMed PMID: 9816363]
[18]
Willis FR, Byrne GC, Jones TW. Fludrocortisone induced heart failure in Addison's disease. Journal of paediatrics and child health. 1994 Jun:30(3):280-1
[PubMed PMID: 8074919]
[19]
Burns A, Brown TM, Semple P. Extreme metabolic alkalosis with fludrocortisone therapy. Postgraduate medical journal. 1983 Aug:59(694):506-7
[PubMed PMID: 6622340]
[20]
Veltri KT, Mason C. Medication-induced hypokalemia. P & T : a peer-reviewed journal for formulary management. 2015 Mar:40(3):185-90
[PubMed PMID: 25798039]
[21]
Harris CL, Raisch DW, Abhyankar U, Marfatia S, Campbell HM, Sather MR. GI risk factors and use of GI protective agents among patients receiving nonsteroidal antiinflammatory drugs. The Annals of pharmacotherapy. 2006 Nov:40(11):1924-31
[PubMed PMID: 17047140]
[22]
Kato J, Mori T, Kamo M, Tanikawa A, Iketani O, Okamoto S. Hypersensitivity to fludrocortisone acetate in a recipient of bone marrow transplantation. Allergology international : official journal of the Japanese Society of Allergology. 2011 Dec:60(4):557-8. doi: 10.2332/allergolint.10-LE-0301. Epub 2011 Jun 25
[PubMed PMID: 21681020]
[23]
Campean R, Hasun M, Stöllberger C, Bucher J, Finsterer J, Schnack C, Weidinger F. Takotsubo-like syndrome triggered by fludrocortisone overdose for Addison's disease: a case report. Journal of medical case reports. 2016 Oct 12:10(1):281
[PubMed PMID: 27729057]
Level 3 (low-level) evidence